PKI Stock Recent News
PKI LATEST HEADLINES
PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
PerkinElmer Inc said it will sell some of its businesses along with the brand name to private equity firm New Mountain Capital for up to $2.45 billion in cash, as it looks to focus on its life sciences and diagnostics businesses under a new name.
PerkinElmer (PKI) delivered earnings and revenue surprises of 14.29% and 2.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022 at 6:00 a.m. ET. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conferenc
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
PerkinElmer's (PKI) newly introduced next-generation, automated GC platform can help simplify lab operations and offer excellent precision for high throughput environments.
PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.
PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.
PerkinElmer's (PKI) introduction of the RUO BioQule NGS System is a cost-effective system that can bring improvements in genomic analysis.
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?